Neurogene Inc. (NGNE)
Fuera de horario:
Neurogene Inc.
535 W 24th Street
5th Floor
New York, NY 10011
United States
(855) 508-3568
https://www.neurogene.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 91
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Rachel L. McMinn Ph.D. | Founder, Executive Chair & CEO | 676.54k | N/D | 1973 |
| Ms. Christine Mikail Cvijic J.D. | President, CFO & Corporate Secretary | 623.29k | N/D | 1978 |
| Dr. Stuart Cobb Ph.D. | Chief Scientific Officer | 478.81k | N/D | 1970 |
| Mr. Arvind Sreedharan | Senior Vice President of Business Operations | N/D | N/D | N/D |
| Ms. Donna M. Cochener-Metcalfe J.D. | Senior VP & General Counsel | N/D | N/D | 1975 |
| Dr. Effie Albanis M.D. | Senior Vice President of Early Clinical & Translational Research | N/D | N/D | N/D |
| Dr. Andrew E. Mulberg CPI, FAAP, M.D. | Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control | N/D | N/D | N/D |
| Mr. Ricardo Jimenez | Senior Vice President of Technical Operations | N/D | N/D | N/D |
| Dr. Julie Jordan M.D. | Chief Medical Officer | N/D | N/D | 1972 |
Descripción
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
Gestión corporativa
La calificación ISS Governance QuickScore de Neurogene Inc. a partir del 1 de mayo de 2024 es 7. Las puntuaciones principales son Auditoría: 4; Junta: 5; Derechos del accionista: 8; Compensación: 9.
